ARCHIVES

Fidaxomicin for CDI Therapy More Cost-Effective Than Vancomycin, Study Says

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Fischinger Names HHS AIDs Coordinator; DeVita Appoints Maryann Roper Acting Deputy Director

October 30, 1987

NCI To File Record No. Of INDS In ’92, Expand Phase 1 Trials

March 6, 1992

Congress Approves FY 1980 HEW Funds

November 23, 1979

ASCO Annual Meeting: PARP Inhibitors Show Promise Against Breast Cancer In Small Phase II Studies

June 5, 2009

NCAB Approves Grants For Action Plan On Breast Cancer

September 22, 1995

Increase Cancer Center Grants More Than R01s, SPOREs, Report Tells NCI

February 28, 2003